Alwin J. Kramer

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2026

68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients.

68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 17, 2026

(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary - Highlights from ESMO 2025 and the First International Cancer of Unknown Primary Meeting.

(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary - Highlights from ESMO 2025 and the First International Cancer of Unknown Primary Meeting.

Journal: Oncology research and treatment

Published: January 30, 2026

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 18, 2025

Etiology of TP53 mutated complex karyotype acute myeloid leukemia.

Etiology of TP53 mutated complex karyotype acute myeloid leukemia.

Journal: Leukemia

Published: August 07, 2025

Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary.

Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary.

Journal: ESMO open

Published: July 30, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.

Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.

Journal: Nature reviews. Clinical oncology

Published: July 10, 2025

Tumour mutational burden: clinical utility, challenges and emerging improvements.

Tumour mutational burden: clinical utility, challenges and emerging improvements.

Journal: Nature reviews. Clinical oncology

Published: July 23, 2024

STIL overexpression shortens lifespan and reduces tumor formation in mice.

STIL overexpression shortens lifespan and reduces tumor formation in mice.

Journal: PLoS genetics

Published: June 19, 2024

Cancer of unknown primary derived from regressed breast cancer.

Cancer of unknown primary derived from regressed breast cancer.

Journal: Journal of cancer research and clinical oncology

Published: April 19, 2024

Showing 1-12 of 139

Last Updated: 09/26/2026